Nyxoah sold 5,674,755 shares at an offering price of USD 9.25 (EUR 8.54) per share. Total gross proceeds of the offering amount to approximately USD 52.5 million (EUR 48.5 million), including the exercise of the underwriters’ option to purchase additional shares for 300,000 shares and before deducting underwriting discounts and commissions and offering expenses.
Nyxoah intends to use the net proceeds from the proposed offering (i) for pre-commercialisation and commercialisation activities in the United States; (ii) to continue gathering clinical data and to support physician initiated clinical research projects related to OSA patient treatments; (iii) to further finance research and development activities related to the next generation of the Genio system and to continue to build a pipeline of new technologies and explore potential collaboration opportunities in the field of monitoring and diagnostics for OSA; and (iv) for other general corporate purposes, including, but not limited to, working capital, capital expenditures, investments, acquisitions, should Nyxoah choose to pursue any, and collaborations. The official press release can be found here.
Philippe Remels led the NautaDutilh team, which further consisted of Lentle Nijs and Don Baudewyns.